Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M. Mok T, et al. Among authors: delmar p. J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160. J Thorac Oncol. 2014. PMID: 24807156 Free article. Clinical Trial.
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J, Au JS, Felip E, Yang PC, Damyanov D, Orlov S, Akimov M, Delmar P, Essioux L, Hillenbach C, Klughammer B, McLoughlin P, Baselga J. Tan EH, et al. Among authors: delmar p. Ann Oncol. 2010 Feb;21(2):217-222. doi: 10.1093/annonc/mdp520. Ann Oncol. 2010. PMID: 20110292 Free PMC article. Clinical Trial.
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA. Van Cutsem E, et al. Among authors: delmar p. J Clin Oncol. 2012 Jun 10;30(17):2119-27. doi: 10.1200/JCO.2011.39.9824. Epub 2012 May 7. J Clin Oncol. 2012. PMID: 22565005 Clinical Trial.
Genetic markers of bevacizumab-induced hypertension.
Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C. Lambrechts D, et al. Among authors: delmar p. Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21. Angiogenesis. 2014. PMID: 24558090
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS. Klughammer B, et al. Among authors: delmar p. J Thorac Oncol. 2016 Apr;11(4):545-55. doi: 10.1016/j.jtho.2015.12.107. Epub 2016 Jan 8. J Thorac Oncol. 2016. PMID: 26773740 Free article.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M. Dimier N, et al. Among authors: delmar p. Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18. Blood. 2018. PMID: 29255066 Free article. Clinical Trial.
44 results